Snowden Capital Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Snowden Capital Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-60,800	Closed	-$10K	–	1182
2022 Q3	$10K	Hold	60,800	–	–	﹤0.01%	1106
2022 Q2	$36K	Buy	60,800 +9,000	+17%	+$8.62K	﹤0.01%	1102
2022 Q1	$68K	Buy	51,800 +23,000	+80%	+$37.3K	﹤0.01%	1007
2021 Q4	$75K	Buy	28,800 +7,800	+37%	+$23.6K	﹤0.01%	926
2021 Q3	$65.3K	Buy	21,000 +1,000	+5%	+$3.34K	﹤0.01%	862
2021 Q2	$74.4K	Hold	20,000	–	–	﹤0.01%	868
2021 Q1	$69.2K	Buy	+20,000	New	+$81.2K	﹤0.01%	790

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Snowden Capital Advisors's PHAS Position: Q4 2022 in Review

Snowden Capital Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 60,800 shares — an estimated $10K sold.

Snowden Capital Advisors first reported a position in PHAS in Q1 2021 and held it in 7 quarters. The position peaked at $75K in Q4 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

Snowden Capital Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Snowden Capital Advisors sold 60,800 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $10K.
Snowden Capital Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Snowden Capital Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $75K in Q4 2021.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Snowden Capital Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.